Orforglipron vs. Semaglutide: A New Era in Diabetes Treatment
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet INDIANAPOLIS, March 24, 2026 — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, … Continue reading Orforglipron vs. Semaglutide: A New Era in Diabetes Treatment →
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet INDIANAPOLIS, March 24, 2026 — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, … Continue reading Orforglipron vs. Semaglutide: A New Era in Diabetes Treatment
What's Your Reaction?
DDP Editor
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
